Poor Investigations, Documentation Lead Form 483 Observations in 2013

Drug Industry Daily
A A
Poor investigations into batch failures and lax procedural documentation were the top reasons drugmakers received FDA Form 483s in 2013.

To View This Article:

Login

Subscribe To Drug Industry Daily